Overview

Study of CXA-10 in Healthy Volunteers

Status:
Completed

Trial end date:
2014-12-01

Target enrollment:

Participant gender:

Summary

This will be the first-in-human (FIH) study with CXA-10. The main purpose of this trial is to demonstrate the tolerability, safety and pharmacokinetics (PK) of CXA-10 at various incremental doses, and to demonstrate the safety and tolerability of the rate of the emulsion vehicle infusion in healthy volunteers. In addition, associated pharmacodynamic (PD) effects of CXA-10 will be investigated.

Phase:

Phase 1

Details

Lead Sponsor:

Complexa, Inc.

Treatments:

CXA-10